Observational studyMultiple sclerosis and related disorders2022

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.

Ethel Ciampi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.